基线FeNO作为未控制中重度哮喘患者后续重度急性发作的预后生物标志物:LIBERTY ASTHMA QUEST研究安慰剂组的事后分析
该事后分析纳入LIBERTY ASTHMA QUEST研究中620例接受安慰剂的中重度未控制哮喘患者,评估基线FeNO对后续重度急性发作的附加预后价值。
要点
- 基线FeNO≥50 ppb与后续重度急性发作风险增加独立相关。
- FeNO≥25 ppb联合血嗜酸性粒细胞≥150 cells/μL及既往≥2次发作风险最高。
- FeNO可能作为哮喘急性发作的附加预后标志物。
核心结论
- 在未控制中重度哮喘中,较高的基线FeNO水平与后续重度急性发作风险增加相关,尤其与嗜酸性粒细胞升高和既往急性发作联合时。
研究设计与样本
- LIBERTY ASTHMA QUEST研究(52周、双盲、3期)的事后分析,纳入620例随机分配至安慰剂的中重度未控制哮喘患者。
临床怎么用
- 对未控制中重度哮喘患者,可结合基线FeNO、血嗜酸性粒细胞计数和既往急性发作史综合评估后续重度急性发作风险。
局限性
- 事后分析,需进一步研究确认FeNO作为哮喘急性发作独立预测因子的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fractional exhaled nitric oxide (FeNO) has potential as a prognostic biomarker in asthma, but its prognostic value among other recognised indicators is unclear. We assessed the added prognostic value of baseline FeNO to blood eosinophil count and prior severe asthma exacerbations for subsequent exacerbations. METHODS: In this post-hoc analysis of the 52-week, double-blind, phase 3 LIBERTY ASTHMA QUEST study, we identified 620 patients with moderate-to-severe asthma who were randomly assigned to placebo; had uncontrolled asthma with inhaled glucocorticoids plus up to two controllers; one or more exacerbations in the previous year; FEV1 percent predicted 40-80%; FEV1 reversibility of 12% or higher and 200 mL; Asthma Control Questionnaire (ACQ-5) score of 1·5 or higher; and complete data on baseline type 2 biomarkers (FeNO, eosinophils, and total IgE) with no baseline minimum requirement. Annualised severe exacerbation rate was assessed by baseline FeNO (<25 ppb, ≥25 to <50 ppb, ≥50 ppb; negative binomial model) and cross-classified by baseline blood eosinophils (<150 cells per μL, ≥150 to <300 cells per μL, ≥300 cells per μL) and prior exacerbations (one, two or more), all adjusted for baseline ACQ-5, postbronchodilator FEV1, and other clinical characteristics. Post-hoc analyses were done in the intention-to-treat population. The LIBERTY ASTHMA QUEST STUDY is registered on ClinicalTrials.gov, NCT02414854, and is complete. FINDINGS: Patients with baseline FeNO of 50 ppb or higher (n=144) had a 1·54-times higher exacerbation rate than patients with FeNO of less than 25 ppb (n=291; relative risk 1·54 [95% CI 1·11-2·14]; p=0·0097). Patients with baseline FeNO of 25 to <50 ppb (n=185) had a 1·33-times higher exacerbation rate than patients with FeNO of less than 25 ppb (1·33 [0·99-1·78]; p=0·0572). Patients with baseline FeNO of 25 ppb or higher, a blood eosinophil count of 150 cells per μL or higher, and two or more prior exacerbations (n=157) had an exacerbation rate 3·62-times higher than patients with FeNO of less than 25 ppb, a blood eosinophil count of less than 150 cells per μL, and one prior exacerbation (n=116; 3·62 [1·67-7·81]; p=0·0011). INTERPRETATION: In uncontrolled, moderate-to-severe asthma, higher baseline FeNO levels were associated with greater risk of severe asthma exacerbations, particularly in combination with elevated eosinophil count and prior exacerbations, supporting the added value of FeNO as a prognostic biomarker. Further research is needed to confirm FeNO as an independent predictor for asthma exacerbations. FUNDING: Sanofi and Regeneron Pharmaceuticals.
引用
- Busse WW, Wenzel SE, Casale TB, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021. PMID: 34181876. doi:10.1016/S2213-2600(21)00124-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。